60 related articles for article (PubMed ID: 15368096)
1. Characterization and Pharmacological Inhibition of the Pore-Forming
Ernst K; Landenberger M; Nieland J; Nørgaard K; Frick M; Fois G; Benz R; Barth H
Toxins (Basel); 2021 May; 13(6):. PubMed ID: 34071730
[TBL] [Abstract][Full Text] [Related]
2. 2019 update of the WSES guidelines for management of
Sartelli M; Di Bella S; McFarland LV; Khanna S; Furuya-Kanamori L; Abuzeid N; Abu-Zidan FM; Ansaloni L; Augustin G; Bala M; Ben-Ishay O; Biffl WL; Brecher SM; Camacho-Ortiz A; Caínzos MA; Chan S; Cherry-Bukowiec JR; Clanton J; Coccolini F; Cocuz ME; Coimbra R; Cortese F; Cui Y; Czepiel J; Demetrashvili Z; Di Carlo I; Di Saverio S; Dumitru IM; Eckmann C; Eiland EH; Forrester JD; Fraga GP; Frossard JL; Fry DE; Galeiras R; Ghnnam W; Gomes CA; Griffiths EA; Guirao X; Ahmed MH; Herzog T; Kim JI; Iqbal T; Isik A; Itani KMF; Labricciosa FM; Lee YY; Juang P; Karamarkovic A; Kim PK; Kluger Y; Leppaniemi A; Lohsiriwat V; Machain GM; Marwah S; Mazuski JE; Metan G; Moore EE; Moore FA; Ordoñez CA; Pagani L; Petrosillo N; Portela F; Rasa K; Rems M; Sakakushev BE; Segovia-Lohse H; Sganga G; Shelat VG; Spigaglia P; Tattevin P; Tranà C; Urbánek L; Ulrych J; Viale P; Baiocchi GL; Catena F
World J Emerg Surg; 2019; 14():8. PubMed ID: 30858872
[TBL] [Abstract][Full Text] [Related]
3. Functional significance of active site residues in the enzymatic component of the
Davies AH; McGlashan J; Posner MG; Roberts AK; Shone CC; Acharya KR
Biochem Biophys Rep; 2016 Dec; 8():55-61. PubMed ID: 28955942
[No Abstract] [Full Text] [Related]
4. WSES guidelines for management of Clostridium difficile infection in surgical patients.
Sartelli M; Malangoni MA; Abu-Zidan FM; Griffiths EA; Di Bella S; McFarland LV; Eltringham I; Shelat VG; Velmahos GC; Kelly CP; Khanna S; Abdelsattar ZM; Alrahmani L; Ansaloni L; Augustin G; Bala M; Barbut F; Ben-Ishay O; Bhangu A; Biffl WL; Brecher SM; Camacho-Ortiz A; Caínzos MA; Canterbury LA; Catena F; Chan S; Cherry-Bukowiec JR; Clanton J; Coccolini F; Cocuz ME; Coimbra R; Cook CH; Cui Y; Czepiel J; Das K; Demetrashvili Z; Di Carlo I; Di Saverio S; Dumitru IM; Eckert C; Eckmann C; Eiland EH; Enani MA; Faro M; Ferrada P; Forrester JD; Fraga GP; Frossard JL; Galeiras R; Ghnnam W; Gomes CA; Gorrepati V; Ahmed MH; Herzog T; Humphrey F; Kim JI; Isik A; Ivatury R; Lee YY; Juang P; Furuya-Kanamori L; Karamarkovic A; Kim PK; Kluger Y; Ko WC; LaBarbera FD; Lee JG; Leppaniemi A; Lohsiriwat V; Marwah S; Mazuski JE; Metan G; Moore EE; Moore FA; Nord CE; Ordoñez CA; Júnior GA; Petrosillo N; Portela F; Puri BK; Ray A; Raza M; Rems M; Sakakushev BE; Sganga G; Spigaglia P; Stewart DB; Tattevin P; Timsit JF; To KB; Tranà C; Uhl W; Urbánek L; van Goor H; Vassallo A; Zahar JR; Caproli E; Viale P
World J Emerg Surg; 2015; 10():38. PubMed ID: 26300956
[TBL] [Abstract][Full Text] [Related]
5. Interaction of the Clostridium difficile Binary Toxin CDT and Its Host Cell Receptor, Lipolysis-stimulated Lipoprotein Receptor (LSR).
Hemmasi S; Czulkies BA; Schorch B; Veit A; Aktories K; Papatheodorou P
J Biol Chem; 2015 May; 290(22):14031-44. PubMed ID: 25882847
[TBL] [Abstract][Full Text] [Related]
6. The host immune response to Clostridium difficile infection.
Solomon K
Ther Adv Infect Dis; 2013 Feb; 1(1):19-35. PubMed ID: 25165542
[TBL] [Abstract][Full Text] [Related]
7. Identification of the cellular receptor of Clostridium spiroforme toxin.
Papatheodorou P; Wilczek C; Nölke T; Guttenberg G; Hornuss D; Schwan C; Aktories K
Infect Immun; 2012 Apr; 80(4):1418-23. PubMed ID: 22252869
[TBL] [Abstract][Full Text] [Related]
8. Uptake of binary actin ADP-ribosylating toxins.
Barth H
Rev Physiol Biochem Pharmacol; 2004; 152():165-82. PubMed ID: 15368096
[TBL] [Abstract][Full Text] [Related]
9. Binary actin-ADP-ribosylating toxins and their use as molecular Trojan horses for drug delivery into eukaryotic cells.
Barth H; Stiles BG
Curr Med Chem; 2008; 15(5):459-69. PubMed ID: 18289001
[TBL] [Abstract][Full Text] [Related]
10. [ADP ribosylation of actin--a cytotoxic principle of bacterial toxins].
Just I; Aktories K
Immun Infekt; 1991 Feb; 19(1):18-21. PubMed ID: 1905678
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the ADP-ribosylation of actin by Clostridium botulinum C2 toxin and Clostridium perfringens iota toxin.
Aktories K; Geipel U; Wille M; Just I
J Physiol (Paris); 1990; 84(4):262-6. PubMed ID: 2079662
[TBL] [Abstract][Full Text] [Related]
12. EGA Protects Mammalian Cells from Clostridium difficile CDT, Clostridium perfringens Iota Toxin and Clostridium botulinum C2 Toxin.
Schnell L; Mittler AK; Sadi M; Popoff MR; Schwan C; Aktories K; Mattarei A; Azarnia Tehran D; Montecucco C; Barth H
Toxins (Basel); 2016 Apr; 8(4):101. PubMed ID: 27043629
[TBL] [Abstract][Full Text] [Related]
13. Actin as target for modification by bacterial protein toxins.
Aktories K; Lang AE; Schwan C; Mannherz HG
FEBS J; 2011 Dec; 278(23):4526-43. PubMed ID: 21466657
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
